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Edited by Laszlo Nagy and Peter TontonozAbstract Dyslipidemia and insulin resistance are commonly
associated with catabolic or lipodystrophic conditions (such as
cancer and sepsis) and with pathological states of nutritional
overload (such as obesity-related type 2 diabetes). Two common
features of these metabolic disorders are adipose tissue dysfunc-
tion and elevated levels of tumour necrosis factor-alpha (TNF-a).
Herein, we review the multiple actions of this pro-inﬂammatory
adipokine on adipose tissue biology. These include inhibition of
carbohydrate metabolism, lipogenesis, adipogenesis and thermo-
genesis and stimulation of lipolysis. TNF-a can also impact the
endocrine functions of adipose tissue. Taken together, TNF-a
contributes to metabolic dysregulation by impairing both adipose
tissue function and its ability to store excess fuel. The molecular
mechanisms that underlie these actions are discussed.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Tumour necrosis factor-alpha (TNF-a) is a multi-functional
cytokine that can regulate many cellular and biological pro-
cesses such as immune function, cell diﬀerentiation, prolifera-
tion, apoptosis and energy metabolism. It is synthesised as a
26-kDa transmembrane monomer (mTNF-a) [1] that under-
goes proteolytic cleavage by the TNF-a converting enzyme
(TACE) to yield a 17-kDa soluble TNF-a molecule (sTNF-
a) [2]. Both sTNF-a and mTNF-a can eﬀect biological and
metabolic responses [3,4] suggesting that mTNF-a may medi-Abbreviations: TNF-a, tumour necrosis factor-alpha; sTNF-a, soluble
tumour necrosis factor-alpha; mTNF-a, transmembrane tumour
necrosis factor-alpha; T2D, type 2 diabetes; TNFR1, tumour necrosis
factor-alpha receptor 1; TNFR2, tumour necrosis factor-alpha recep-
tor 2; WAT, white adipose tissue; BAT, brown adipose tissue; PPARc,
peroxisome proliferator-activated receptor gamma; C/EBPa, CCAAT/
enhancer binding protein; LPL, lipoprotein lipase; HSL, hormone
sensitive lipase; NFjB, nuclear factor-kappa B; IjB, inhibitor of
NFjB; IKKb, IjB kinase beta; JNK, c-jun N-terminal kinase; ERK1/
2, extracellular signal-regulated kinase; AMPK, AMP-activated pro-
tein kinase
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doi:10.1016/j.febslet.2007.11.051ate paracrine and autocrine signals, leaving sTNF-a to mediate
endocrine eﬀects [5]. However, more recent indications are that
the endocrine actions of sTNF-a depend on the maintenance
of high circulating levels, which are more likely to occur in cat-
abolic disease states such as the cachectic conditions associated
with sepsis and cancer. In contrast, in obesity-related type 2
diabetes (T2D) the levels of both mTNF-a and sTNF-a are in-
creased in adipose tissue [6,7] but circulating levels of sTNF-a
are lower than in the catabolic diseases. Therefore whether adi-
pose-derived sTNF-a exerts endocrine eﬀects in systemic insu-
lin resistance has been debated. Initially, circulating levels were
often found to be low and sometimes not signiﬁcantly elevated,
prompting the conclusion that adipose tissue does not release
TNF-a systemically. However, with the improved sensitivity
and speciﬁcity of detection reagents, circulating sTNF-a now
seems well correlated to BMI [8] and impairment in TNF-a
processing can improve systemic insulin sensitivity [9,10].
Moreover, the diﬀuse nature of adipose tissue and its close
association with metabolically relevant tissues such as muscle
and pancreas suggests that the local but chronic production
of adipose tissue-derived sTNF-a may still target non-adipose
tissues during obesity. The conﬁrmation that cytokine-produc-
ing macrophages are present in adipose tissue of obese diabet-
ics further supports this notion [11]. Whether this also
implicates TNF-a produced by resident macrophages (e.g.
Kupﬀer cells) in the physiological regulation of energy metab-
olism in other tissues such as liver remains to be established.
Importantly, as outlined in this review, adipose tissue-derived
TNF-a can also aﬀect systemic energy homeostasis indirectly
by regulating both adipose function and expandability. This
is pertinent to our understanding of the mechanisms of
TNF-a action in obesity-associated metabolic dysregulation.
Evidence that TNF-a can itself impact on cellular metabo-
lism in catabolic disease states dates back to the early 1980s
when it was ﬁrst puriﬁed and conﬁrmed to be the long
sought-after cancer toxin and also the cachexia-inducing fac-
tor, cachectin. More recently, TNF-a was shown to be relevant
to adipocyte metabolism. In vitro studies initially suggested
that TNF-a aﬀects glucose homeostasis in adipocytes [12], pro-
motes lipolysis in cultured adipocytes [13] and potently inhibits
adipocyte diﬀerentiation and lipogenesis [14,15]. However, the
ﬁrst demonstration that TNF-a may be relevant to metabolic
diseases associated with overnutrition (such as obesity-related
T2D) was made by Hotamisligil and colleagues, who showed
that TNF-a is elevated in adipose tissue from obese diabetic
rodents and is a mediator of obesity-related insulin resistance
and T2D [6].blished by Elsevier B.V. All rights reserved.
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from studies showing that genetic blockade of TNF-a action
can restore insulin sensitivity in vitro and in vivo [16,17]. Thus,
TNF-a production appears to contribute to the pathogenesis
of rodent obesity-induced insulin resistance. Evidence that this
is also true for humans has been less well established and com-
plicated by inconsistent early correlations of circulating sTNF-
a with obesity. Additionally, several studies found that short-
term treatment with an anti-TNF-a antibody [18,19] or with a
sTNFR1-IgG1 chimera [20,21] failed to improve insulin sensi-
tivity in obese type 2 diabetics or subjects with visceral obesity.
One problem with interpreting these negative ﬁndings comes
with the diﬃculty in determining whether local TNF-a activity
(both mTNF-a and sTNF-a) is completely neutralised by such
acute treatment. They also contrast with recent reports that
ﬁnd more chronic treatment with anti-TNF-a antibodies im-
proves insulin sensitivity in both lean [22–24] and obese pa-
tients [25]. Furthermore, mounting evidence suggests that
human obesity promotes a state of chronic, low-grade inﬂam-
mation that contributes to insulin resistance and T2D. Taken
together, TNF-a and/or its mechanisms of action might serve
as a therapeutic targets to treat disorders associated with
chronic inﬂammation, impaired glucose tolerance and dyslip-
idaemia.
1.1. What is the cellular source of adipose tissue-derived
sTNF-a?
The vast majority of adipose tissue volume is comprised of
lipid-laden adipocytes, and both isolated or diﬀerentiated adi-
pocytes can produce TNF-a. Hence, it was initially assumed
that adipocytes were the predominant source of the elevated
adipose tissue TNF-a in obesity. However, adipose tissue also
contains a signiﬁcant stromovascular fraction (SVF), which
contains numerous metabolically relevant cell types. These in-
clude preadipocytes, endothelial cells, smooth muscle cells,
ﬁbroblasts, leukocytes and macrophages, and more recent
studies have demonstrated that these SVF cells can produce
substantially more TNF-a than adipocytes [11,26–28]. Indeed,
obesity is associated with an increased inﬁltration of macro-
phages into adipose tissue [11,27,29,30], and it is likely that
these adipose tissue macrophages (ATMs) are predominantly
responsible for the elevated production of TNF-a during obes-
ity [11]. Furthermore, recent mouse models have demonstrated
that both the recruitment and classical activation of ATMs are
required for the development of insulin resistance that is asso-
ciated with obesity. Intriguingly, a recent study reports that,
although macrophage-derived TNF-a can impair insulin sensi-
tivity in TNF-a KO mice, the absence of TNF-a in macro-
phages only does not protect otherwise wild-type mice from
the development of obesity-related insulin resistance [31].
Hence the relative contribution of macrophage and non-mac-
rophage-derived TNF-a to obesity-induced insulin resistance
remains incompletely understood.
1.2. What induces TNF-a expression in adipose tissue?
An important question that remains incompletely addressed
is the nature of the original trigger that induces TNF-a pro-
duction in adipose tissue. The regulation of TNF-a gene tran-
scription clearly is cell type-speciﬁc, however since the vast
majority of TNF-a production comes from classically acti-
vated macrophages, much interest is focused on identifying
the initial trigger(s) that stimulate recruitment and activationof these immune cells into adipose tissue. One hypothesis is
that increased adipocyte death in expanding adipose tissue
may induce chemoattractant signals that recruit monocytes.
Indeed, obesity in both rodents and humans is associated with
increased numbers of apoptotic and necrotic adipocytes in
white and brown adipose tissue (WAT and BAT, respectively)
[32–34], and one study ﬁnds that the majority of macrophages
in WAT of obese mice and humans are localised to dead adi-
pocytes [34]. That obesity is associated with increased adipo-
cyte death is consistent with the notion that adipose tissue
may have a limited capacity for expansion that is reached dur-
ing chronic over-nutrition. However, since secreted cytokines
can also stimulate further cytokine production from and pro-
mote apoptosis of target cells, it is not currently apparent
which is cause or consequence.
Nonetheless, it is clear that proper immune function is clo-
sely linked to nutritional status [35], and this may be due to
the fact that dietary fatty acids (FA) can alter cytokine produc-
tion [36]. This has prompted the alternative but not mutually
exclusive suggestion that dietary components, in particular
speciﬁc fats, may play a signiﬁcant role in regulating the
inﬂammatory proﬁle of adipose tissue, at least in diet-induced
obesity. Indeed, n6 FA appear to be pro-inﬂammatory
whereas long-chain, marine-derived n3 FA elicit anti-athero-
genic and anti-inﬂammatory eﬀects. Intriguingly, calorie
restriction and weight loss are associated with decreased cyto-
kine production [37], providing a rational basis for nutritional
strategies that target immune modulation.
With respect to TNF-a production speciﬁcally, levels of this
cytokine are known to be nutritionally regulated but, impor-
tantly, can be enhanced by hyperinsulinaemia alone [38]. How-
ever, it is currently unclear whether the elevated production of
TNF-a in obesity-related diabetes occurs secondarily to hyper-
insulinaemia. Furthermore, in vivo cytokine action results from
a complex interplay between networks of pro- and anti-inﬂam-
matory cytokines. It is therefore likely that a co-ordinate reg-
ulation of anti-inﬂammatory cytokines such as IL-10 may play
a role in both TNF-a production and action in vivo.1.3. Molecular mechanisms of TNF-a action in adipocytes
TNF-a mediates its biological eﬀects on adipose tissue via
two distinct cell surface receptors: tumour necrosis factor-
alpha receptor 1 (TNFR1) (a 55- or 60-kDa peptide in rodents
and humans, respectively); and tumour necrosis factor-alpha
receptor 2 (TNFR2) (a 75- or 80-kDa peptide in rodents and
humans, respectively). Both receptors are ubiquitously ex-
pressed transmembrane glycoproteins that trimerise upon li-
gand binding. Like TNF-a, both TNFRs can be
proteolytically cleaved to release soluble forms (sTNFR).
These may be involved in the neutralisation and excretion of
TNF-a and thereby may modulate TNF-a activity both tem-
porally and spatially [39]. These soluble receptors may also
be more accessible biomarkers for elevated TNF-a activity.
The circulating levels of both soluble TNFRs can be nutrition-
ally regulated [8] and have been reported to increase in both
obesity and in non-obese adults with pro-atherogenic lipid pro-
ﬁles [40,41].
Although TNFR1 and TNFR2 are highly homologous in
their ligand-binding extracellular domains, their intracellular
domains exhibit no sequence homology and they activate
divergent signalling pathways [42]. Results from numerous
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mediate the majority of eﬀects of TNF-a on adipose tissue
function. Human and murine TNF-a are equally eﬀective at
impairing insulin signalling in murine adipocytes [43]. This
suggests that signals transduced via TNFR1 are suﬃcient for
this eﬀect, because human TNF-a can only activate murine
TNFR1 [44]. Furthermore, lack of TNFR1, but not lack of
TNFR2, signiﬁcantly improves insulin sensitivity in ob/ob mice
and cultured adipocytes [45,46]. Finally, studies using TNFR1
and/or TNFR2-deﬁcient preadipocytes show that it is TNFR1
that is required for the inhibition of adipogenesis by both sol-
uble and transmembrane TNF-a [4,47]. Thus, TNF-a modu-
lates adipose tissue function predominantly through TNFR1.
Nevertheless, other studies suggest that TNF-a may also medi-
ate some eﬀects on adipocytes through TNFR2 [40,48–50].
However, knowledge of the exact role of TNFR2 in TNF-a-
mediated adipose tissue dysfunction is limited. In contrast,
many of the signalling pathways activated via TNFR1 have
been implicated in mediating the actions of TNF-a on adipose
tissue (Fig. 1). Herein, we will limit our discussion to the path-
ways that have been shown to eﬀect aspects of adipocyte biol-
ogy speciﬁcally.
Neither TNFR has intrinsic catalytic activity. Instead, they
can transmit signals by recruiting intracellular adapter pro-
teins, which interact with distinct domains of the cytoplasmic
portions of the receptors to activate speciﬁc downstream sig-
nals. For example, several adapter complexes are recruited to
the trimeric death domain of TNFR1 (TNFR1-DD), which
has been implicated in mediating many of the eﬀects of
TNF-a on adipocyte biology [47,51] (Fig. 1). As its name indi-
cates the TNFR1-DD is responsible for the cytotoxic signals
induced by TNF-a. However, as with many TNF-a actions,
these can be cell type-speciﬁc; although preadipocytes are more
sensitive to TNF-a-induced cell death, TNF-a can also induce
apoptosis in adipocytes [52,53]. This is likely to be mediated by
TNFR1, at least in brown adipocytes [53].
The TNFR1-DD can also activate cell survival and pro-
inﬂammatory signalling pathways that lead to the activation
of nuclear factor-kappa B (NFjB) and of mitogen-activated
protein kinase (MAPK) cascades, such as those involving
extracellular signal-regulated protein kinase (ERK), p38
MAPK and c-Jun N-terminal kinase (JNK) (Fig. 1). These sig-
nalling pathways have been reported to be activated by TNF-a
in adipose tissue and remain good candidates for mediating
metabolic dysregulation [54–58]. However, TNFR1 and its
DD can activate a number of additional signalling pathways
with metabolic relevance to adipocyte biology, such as acidic
sphingomyelinase (aSMase), nuclear factor of activated T-cells
(NFAT), protein kinase A (PKA), CREB, protein kinase C
(PKC), PI3K and calcium release (Fig. 1). However, the recep-
tor-proximal events that lead to these remain to be completely
elucidated, as do the mechanisms that facilitate sustained
TNF-a-induced signalling.
2. TNF-a and adipocyte insulin resistance
Adipose tissue is a key regulator of systemic carbohydrate
metabolism and may play an important role in glucose sensing.
This is supported by the fact that mice engineered to selectively
lack the glucose transporter GLUT4 in their adipose tissue de-
velop insulin resistance in liver and skeletal muscle, resulting in
systemic glucose intolerance and hyperinsulinaemia [59]. It isnow well established that TNF-a can induce a state of insulin
resistance in adipocytes [60]. Indeed, the mechanisms underly-
ing this eﬀect have been the subject of intense research. Early
reports identiﬁed that TNFR1-induced signals are required
and suﬃcient to impair insulin action [43,46,48], and a recent
report suggests that these can be narrowed down to those in-
duced by the TNFR1-DD [51]. However, several downstream
mechanisms have been proposed by which TNF-a might cause
insulin resistance in adipose tissue. These are discussed next.2.1. Transcriptional mechanisms of TNF-a-induced insulin
resistance
TNF-a suppresses the expression of many proteins that are
required for insulin-stimulated glucose uptake in adipocytes,
such as the insulin receptor (IR), insulin receptor substrate-1
(IRS-1) and GLUT4 [61–63]. Although mechanisms such as
accelerated proteasomal degradation (e.g. IRS-1) and impaired
translation may be important, more is known about how TNF
alters their expression at the transcriptional level.
Amongst the ﬁrst transcription factors shown to be targeted
by TNF-a signalling in adipocytes was the adipogenic master
regulator, peroxisome proliferator-activated receptor gamma
(PPARc) [64–66]. TNF-a can target PPARc by inhibiting the
expression of PPARc mRNA and also through suppression
of its transcriptional activity. The latter can occur by promot-
ing serine phosphorylation of key regulatory residues in the N-
terminal domain of PPARc (e.g. S112 in murine PPARc2 or
S84 in human PPARc1) [67,68]. This phosphorylation event
can be mediated by JNK and extracellular signal-regulated ki-
nase (ERK1/2) [67,68] and has been implicated in TNF-a-in-
duced suppression of PPARc in hepatic stellate cells [69].
Furthermore, in vitro over expression of PPARc S112A in
3T3-L1 adipocytes prevents the TNF-a-mediated downregula-
tion of IRS-1 [70], and mice with a homozygous S112A muta-
tion in PPARc remain insulin-sensitive on a high fat diet [71].
Hence, TNF-a may suppress PPARc activity in adipocytes by
promoting its phosphorylation. TNF-a may also inhibit
PPARc activity through activation of the classic TNF-a-in-
duced transcription factor, NFjB. Speciﬁcally, p65/RelA has
been suggested to directly bind to PPARc in complex with
its co-activator, PGC1, thereby preventing binding to PPARc
response elements [57]. This is consistent with the observation
that p65 can suppresses PPARc activity in the absence of any
NFjB DNA-binding sites [66].
Suppression of PPARc mRNA levels is also observed fol-
lowing treatment with TNF-a. How this is achieved remains
incompletely understood. One mechanism stems from the sug-
gestion that PPARc expression is itself upregulated by PPARc
activity. Hence, in TNF-a-treated adipocytes, downregulation
of PPARc activity is likely to also result in reduced mRNA
levels. This would also be true for another adipogenic tran-
scription factor and PPARc target gene, CCAAT/enhancer
binding protein (C/EBPa). TNF-a also suppresses C/EBPa
mRNA expression. Since the GLUT4 promoter contains re-
sponse elements for, and is regulated by, both PPARc and
C/EBPa [54], it is likely that TNF-a can suppress GLUT4
expression via a PPARc and C/EBPa-dependent mechanism.
Whether this is true for all genes that are downregulated in
insulin-resistant adipose tissue is unclear.
Recently, the protein kinase mitogen activated protein
kinase kinase kinase kinase 4 (MAP4K4), an activator of the
Fig. 1. Signalling pathways induced by TNF-a in adipose tissue. Upon TNFR1 activation the adapter molecule TRADD (TNFR-associated death
domain protein) interacts with the TNFR1-DD. TRADD recruits downstream adapter molecules such as Fas-associated death domain protein
(FADD), TNFR-associated factor 2 (TRAF2), receptor-interacting protein 1 (RIP1) and mitogen-activated protein kinase (MAPK)-activating death
domain protein (MADD). These adapters then mediate the activation of divergent downstream signalling pathways. Apoptosis: FADD recruits
caspases such as caspase 8 to TNFR1, thereby forming the TNFR1 death-inducing signalling complex (DISC). This complex activates downstream
caspases, leading to apoptosis. Ceramide production: the TNFR1-DD activates acidic sphingomyelinase (aSMase), which hydrolyses sphingolipids to
produce ceramide. Ceramides can be converted into toxic lipids, such as the ganglioside GM3. Ceramides and gangliosides may then mediate
transcriptional eﬀects, possibly by activation of NFjB. Ceramides can also stimulate apoptosis and impair insulin signalling, and both ceramide and
caspases may inhibit AKT. NFjB activation: TRAF2 and RIP1 mediate NFjB activation by recruiting the IKK (inhibitor of NFjB (IjB) kinase)
complex to TNFR1. TRAF2 interacts with IKKb and IKKa, and also promotes the K63-linked polyubiquitination of RIP1 (Ub, ubiquitin);
Ubiquitinated RIP1 binds to IKKc. TRAF2 also recruits TAK1 (TGFb-activated kinase 1) to TNFR1 via an interaction with TAB1 (TAK1 binding
protein 1), which may result in activation of TAK1. This also brings TAK1 into close proximity of the IKK complex. TAK1 may activate IKKb
either by phosphorylating it directly, or by activating NIK (NFjB-inducing kinase), which then phosphorylates IKKb. Active IKKb phosphorylates
IjBa on conserved serines, leading to its polyubiquitination and proteasomal degradation. This liberates the bound NFjB dimers (e.g. the
prototypical p65/p50 heterodimer), which translocate into the nucleus to mediate transcriptional eﬀects. MAPK activation: TNF-a activates various
MAPKs in adipocytes, including ERK1/2, p38 MAPK and JNK, possibly via the adapter MADD. ERK1/2 and JNK can each regulate transcription
by suppressing the activity of PPARc. JNK may also exert transcriptional eﬀects via c-jun. JNK, ERK1/2, IKKb and other kinases have also been
implicated in TNF-a-induced serine phosphorylation of IRS-1, which suppresses insulin signalling. Other eﬀects: TNF-a can activate PKA (protein
kinase A) by increasing cAMP levels, possibly via transcriptional eﬀects. TNF-a can activate the transcription factor NFAT via Ca2+, however this
has not been established in adipocytes. In preadipocytes TNF-a can stimulate transcription by TCF7L2 (transcription factor 7-like 2). The
transcriptional eﬀects of TNF-a promote ER stress, oxidative stress and mitochondrial dysfunction, lipolysis and altered adipokine expression,
thereby compromising insulin signalling and adipocyte lipid metabolism. TNFR2 may also mediate some eﬀects of TNF-a in adipose tissue, albeit by
unknown mechanisms. Factors that have not been directly established in TNF-a-induced signals in adipocytes are faded. Dashed lines indicate eﬀects
that are mediated by indirect or unestablished mechanisms. Question marks indicate eﬀects that remain to be fully established. Genes written in red
or green are upregulated or downregulated by TNF-a, respectively.
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induced suppression of PPARc and GLUT4 mRNA in adipo-
cytes [72]. TNF-a upregulates MAP4K4 expression in mature
adipocytes in a TNFR1-dependent manner, and knockdownof MAP4K4 attenuates TNF-a-induced suppression of
GLUT4 expression [72,73]. Hence MAP4K4 may contribute
to the suppression of PPARc and GLUT4 by TNF-a
(Fig. 1). However, how MAP4K4 activation leads to the sup-
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of MAP4K4 in the pathogenesis of metabolic complications
in vivo.
The transcriptional events required for TNF-a-induced insu-
lin resistance may also involve the transcriptional activity of
NFjB itself, and hence NFjB target gene expression. How-
ever, this has yet to be formally demonstrated with respect
to TNF-a-induced insulin resistance in adipocytes. Despite
this, there is ample evidence to support the requirement for
the upstream signals that lead to NFjB activation in TNF-
a-induced insulin resistance in vitro and in vivo [63,74–76]. Fur-
thermore, several potential NFjB target genes that are upreg-
ulated by TNF-a in adipocytes have been implicated in
adipocyte insulin resistance. One example is suppressor of
cytokine signalling-3 (SOCS-3), which inhibits IR-dependent
IRS-1 tyrosine phosphorylation and thereby suppresses insu-
lin-stimulated glucose uptake [77–79] (Fig. 2). Overexpression
of SOCS-3 in adipose tissue causes local insulin resistance [80],
whereas knockdown of SOCS-3 in adipocytes attenuates the
TNF-a-mediated suppression of tyrosine phosphorylation of
IRS-1 and IRS-2 [79]. Hence, the upregulation of SOCS-3
may contribute to TNF-a-mediated suppression of IR-proxi-
mal signalling (Fig. 2).
Finally, TNF-a may induce insulin resistance through the
upregulation of PP2C gene expression, resulting in suppression
of AMP-activated protein kinase (AMPK) activity. This hasFig. 2. Mechanisms of TNF-a-induced insulin resistance in adipose tissue. Ins
The IR has intrinsic tyrosine kinase activity, and insulin binding promotes au
the recruitment of insulin receptor substrates (IRS) such as IRS-1. IR-bou
allowing the activation of signalling pathways such as phosphatidylinosito
translocation of GLUT4 from intracellular storage vesicles to the plasma m
proximal signalling. TNF-a also impairs IR-proximal signalling through the
described in Figure 1. TNF-a further compromises insulin action through tran
downregulation of components required for insulin responsiveness and upr
insulin sensitivity, such as SOCS-3. Transcriptional eﬀects may also promote
(TZD) impair TNF-a-induced insulin resistance. Black arrows indicate eﬀe
antagonise insulin signalling. Eﬀects on gene expression are indicated as desrecently been implicated in skeletal muscle insulin resistance
[81]. Whether this occurs in adipose tissue remains to be deter-
mined. However, given that metformin may be able to reverse
some actions of TNF-a in adipose tissue [82], this seems an
intriguing possibility (Fig. 2).
2.2. Crosstalk between TNF-a and proximal insulin signalling
TNF-a can also compromise IR/IRS-1 signalling indepen-
dently of transcriptional regulation [83]. This is thought to oc-
cur by direct signalling events that mediate a crosstalk between
TNFR1-induced pathways and proximal insulin signals (Figs.
1 and 2). Indeed, TNF-a inhibits insulin-stimulated tyrosine
phosphorylation of both the IR and IRS proteins. The latter
has been best studied and occurs by induction of serine phos-
phorylation of IRS-1 [43,84,85]. Over 20 IRS-1 serine kinases
and an even greater number of putative serine phosphorylation
sites have been implicated in the negative regulation of insulin
signalling. In vitro studies have established that some sites can
be phosphorylated by multiple serine kinases and numerous
sites can be phosphorylated by the same kinase [85]. Whether
these kinases are also relevant in vivo has begun to be substan-
tiated by investigations of their genetic ablation, at least for
JNK, PKCh and IjB kinase beta (IKKb) (liver-speciﬁc), in ro-
dent models of obesity and insulin resistance. The use of site-
speciﬁc antibodies has also been instrumental in dissecting the
involvement of site-speciﬁc kinase activities in stimulus-in-ulin mediates metabolic eﬀects by binding to the insulin receptor (IR).
tophosphorylation of the IR on key intracellular tyrosines. This allows
nd IRS proteins are themselves phosphorylated on tyrosine residues,
l 3-kinase (PI3K) and AKT. These exert downstream eﬀects such as
embrane. Protein tyrosine phosphatases (PTPases) can abrogate IR-
activation of IRS serine kinases and the production of toxic lipids, as
scriptional eﬀects, possibly mediated via NFjB activation. These cause
egulation of factors that may further impair both local and systemic
cellular stresses that can impair insulin signalling. Thiazolidinediones
cts that promote insulin signalling. Red arrows indicate eﬀects that
cribed in Fig. 1.
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phosphorylation sites have been studied with respect to
TNF-a action in adipocytes. One site that has been well char-
acterised is serine 307 in rIRS1 (corresponding to S312 in hu-
man IRS-1). Phosphorylation of this residue impairs IR-IRS
interactions and promotes IRS-1 degradation (Fig. 2) [86–
88]. Studies with pharmacological inhibitors and/or activators
have implicated numerous upstream kinases in IRS-S307 phos-
phorylation, including ERK1/2 [83,86], JNK [87,89], IKKb
[90], and mTOR [91]. Although each of these can be activated
by TNF-a, not all of these have been demonstrated to directly
interact with endogenous IRS-1 in adipocytes and the sequen-
tial nature of the signalling cascade(s) remains to be delineated.
Furthermore additional kinases such as PKC isoforms have
also been implicated in TNF-a-induced insulin resistance in
non-adipose cells and these may also be involved in Ser307
phosphorylation in adipocytes.
In addition to impairing protein–protein interactions, TNF-
a-induced serine phosphorylation can also disrupt protein–
phospholipid interactions. Recently, our laboratory and others
have independently identiﬁed S24 of IRS-1 as a substrate site
for PKC and IRAK [92,93]. This single modiﬁcation is suﬃ-
cient to impair lipid binding, intracellular localisation of the
IRS1-PH domain and reduce IR–IRS1 interactions and signal-
ling. This ultimately reduces insulin-stimulated signalling and
glucose uptake. TNF-a, IL-1 or the diacylglycerol mimetic,
phorbol 12-myristate 13-acetate (PMA), can all induce phos-
phorylation of S24. However, unlike S307 or S612, this site
is not phosphorylated following chronic insulin treatment or
by C-2 ceramides [93]. Hence, this represents a modiﬁcation
of IRS-1 that is regulated by a limited range of pathological
stimuli and that may not play a role in physiological negative
feedback regulation of insulin signalling.
In addition to altering cellular serine kinase activity, TNF-a
action can alter membrane lipid composition and increase the
availability of reactive lipids such as diacylglycerols and cera-
mides (Figs. 1 and 2). These can lead to insulin resistance
through several means, including activating serine kinase sig-
nalling cascades and altered membrane ﬂuidity, which impairs
receptor internalisation, cycling and function. TNF-a-induced
generation of ceramides has previously been linked to insulin
resistance via IRS-1 serine kinases [43,94–97] (Fig. 2) and cer-
amide biosynthesis has recently been suggested to be required
for rodent obesity-induced insulin resistance in vivo [98]. Fur-
thermore, ceramides can be metabolised to glycosphingolipids
and gangliosides such as GM3, which have also been shown to
alter IR tyrosine kinase signal transduction [99] (Fig. 2). In-
deed, we have shown that TNF-a raises GM3 levels in adipo-
cytes and both obesity- and TNF-a-induced insulin resistance
can be reversed by inhibiting the activity of glucosylceramide
synthase, a key enzyme in the synthesis of glycosphingolipids
and gangliosides [100]. Hence, TNF-a-induced insulin resis-
tance can be mediated through TNFR1-dependent signals that
activate SMase and thereby increase the levels of ceramides
and gangliosides (Figs. 1 and 2).2.3. Role of TNF-a in obesity-associated ER stress, oxidative
stress and mitochondrial dysfunction
Obesity-related insulin resistance has recently been linked to
oxidative stress and organelle dysfunction, i.e. mitochondrial
dysfunction and endoplasmic reticulum (ER) stress [35]. Theseare all features that can also be induced by TNF-a and which
have been linked to activation of the JNK or NFjB pathways
(Figs. 1 and 2). Indeed, it has been suggested that production
of reactive oxygen species (ROS) contributes to both TNF-a-
induced NFjB activation [101] and TNF-a-induced insulin
resistance [102] (Fig. 2). Additionally, oxidative stress may
promote increased production of TNF-a under adverse meta-
bolic conditions [103]. Interestingly, in adipose tissue TNF-a
upregulates the expression of many genes that encode proteins
involved in responses to ER stress or oxidative stress [62] (Figs.
1 and 2). Furthermore, TNF-a downregulates the expression
of genes that encode components of the electron transport
chain [104] and may thereby induce mitochondrial dysfunc-
tion. Indeed, TNF-a has recently been shown to inhibit FA
oxidation in diﬀerentiated human adipocytes [104].3. TNF-a and adipocyte endocrinology
Adipose tissue is now also recognised as an endocrine organ
that secretes many products that can impact on numerous as-
pects of whole organism biology, including energy homeosta-
sis, immune function and reproduction [105]. Several of these
adipose tissue-derived secreted proteins, termed adipokines,
are also involved in obesity-related metabolic complications.
Interestingly, TNF-a action on adipose tissue can alter the
production of many adipokines and this is relevant to the sys-
temic eﬀects of TNF-a on insulin sensitivity and whole body
energy homeostasis (Fig. 2).
3.1. Insulin-sensitising adipokines
The principle insulin-sensitising adipokines are adiponectin
and leptin [105]. Adiponectin enhances insulin sensitivity and
improves the serum lipid proﬁle through AMPK activation
and increased FA oxidation [106,107]. Conversely, disruption
of adiponectin expression causes insulin resistance [108].
TNF-a may therefore induce systemic insulin resistance and
dyslipidaemia by suppressing the production of adiponectin
[63,109–111]; indeed, circulating levels of adiponectin inversely
correlate with plasma levels of TNF-a [112,113]. The mecha-
nism by which this is mediated is likely to involve suppression
of PPARc [114], C/EBPb [115] and/or through JNK activation
[58,88].
The regulation of leptin production by TNF-a is less clear.
Instead of reducing the production of this insulin-sensitiser,
TNF-a promotes leptin release from adipocytes, [116,117]
and circulating TNF-a levels positively correlate with serum
leptin concentrations in obese patients with T2D [118,119].
In the absence of TNF-a, obesity-induced hyperleptinaemia
is signiﬁcantly reduced. However, the mechanism by which this
is mediated is currently unclear as the transcriptional upregu-
lation is context-dependent [116,120,121].
Visfatin (also called PBEF/Nampt) has recently been identi-
ﬁed as a putative adipokine that is secreted by visceral fat and
that stimulates insulin signalling [122]. However, the debate
regarding its role as an adipokine continues [123], and studies
investigating the eﬀects of TNF-a on visfatin expression have
yielded conﬂicting results; whereas TNF-a can suppress expres-
sion of visfatin in 3T3-L1 adipocytes [124], one recent study
suggests that TNF-a markedly upregulates visfatin expression
in human adipose tissue [125]. Hence the exact role of visfatin
and its regulation by TNF-a requires further investigation.
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In non-obese healthy subjects, the cytokine-mediated inter-
play between the immune system and adipose tissue maybe
the means of releasing surplus fuel for utilisation by activated
immune cells during infection and/or inﬂammation. TNF-a
can regulate the production of other pro-inﬂammatory cyto-
kines (e.g. IL-6 and IL-1) and thereby further mediate and/
or amplify its eﬀects on peripheral organs.
Resistin was originally implicated in the pathogenesis of
obesity-associated insulin resistance in mice [126], whereas
such a role in humans is still debated. This is due in part to spe-
cies-speciﬁc diﬀerences in its cellular source [127]. Nonetheless,
in humans, resistin has many features of a pro-inﬂammatory
cytokine and may play a role in inﬂammatory diseases. Some
studies suggest that regulatory interactions exist between
TNF-a and resistin, but these may also be cell type-speciﬁc.
TNF-a suppresses expression of resistin in 3T3-L1 adipocytes
[128], whereas it promotes expression of resistin from human
peripheral blood mononuclear cells (PBMC) [129]. The latter
may be a major source of resistin in humans. Conversely, hu-
man resistin promotes the expression of TNF-a and other
cytokines by various cell types via an NFjB-dependent path-
way [129,130]. Therefore, in the context of the metabolic syn-
drome, it is possible that increased expression of resistin could
contribute to the elevated levels of adipose tissue TNF-a dur-
ing obesity. This possibility has yet to be investigated.
3.3. PAI-1
Although plasminogen activator inhibitor-1 (PAI-1) has tra-
ditionally been linked to the pathogenesis of atherosclerosis,
recent evidence suggests that it is also involved in the develop-
ment of obesity and insulin resistance [131]. TNF-a upregu-
lates PAI-1 expression in adipocytes and adipose tissue via a
pathway that involves activation of p42/p44, PKC, p38, PI3-
K, NFjB and ROS production [50,63,132–135] (Fig. 2). Inter-
estingly, TNFR2-derived signals may actually attenuate the
induction of PAI-1 expression by TNF-a [50] (Fig. 1). Never-
theless, TNF-a is likely to contribute to obesity-associated in-
creases in PAI-1 and may thereby promote the cardiovascular
complications of metabolic syndrome.4. TNF-a and adipocyte lipid metabolism
The most distinguishing aspect of adipocytes is their ability
to store (through lipogenesis) and release (through lipolysis
and/or thermogenesis) surplus energy appropriately. Hence
proper adipocyte function plays a pivotal role in the regulation
of whole-body lipid metabolism. These functions can be regu-
lated by numerous extracellular stimuli, such as insulin, corti-
sol, catecholamines, growth hormone, testosterone, free fatty
acids (FFA) and cytokines [136]. TNF-a action on adipocytes
can directly alter lipid metabolism through inhibition of FFA
uptake and lipogenesis and stimulation of FFA release via
lipolysis. In this way, adipose tissue-derived TNF-a can con-
tribute to the development of dyslipidaemia and resultant met-
abolic complications.
4.1. Inhibition of fatty acid uptake and lipogenesis by TNF-a
In adipocytes excess energy is stored in the form of lipid
droplets rich in neutral triacylglycerols (TAG). TAG synthesis
(or lipogenesis) results from the esteriﬁcation of FA-derivedAcyl CoA and Gycerol-3-P. FA are derived from three
sources: (a) from the circulation, (b) from lipolysis of intracel-
lular TAG or (c) de novo FA synthesis from glucose. Similarly,
Glycerol-3-P can be sourced from glycerol, glucose, and amino
acids (Fig. 3A). Hence, the overall metabolic ﬂux of lipids into
TAG is dependent on the availability of relevant substrates
and the regulation of several enzymatic pathways, which
may include those that are not classically thought of as lipo-
genic.
By inducing adipocyte insulin resistance, TNF-a can impair
glucose uptake into adipocytes. TNF-a also inhibits the uptake
of FFA. Although the mechanism of FFA uptake is being de-
bated, TNF-a does downregulate the expression of FA trans-
port protein (FATP) and translocase (FAT) in adipose tissue
[137], as well as the FA-binding protein FABP4/aP2. FFA up-
take into adipocytes is also facilitated by the extracellular
expression and activity of lipoprotein lipase (LPL) [136].
TNF-a has been shown to downregulate LPL expression in
both murine adipose tissue and in 3T3-L1 adipocytes [62,66],
likely via a TNFR1-dependent pathway [138]. However, stud-
ies investigating the eﬀect of TNF-a on LPL expression in hu-
man adipose tissue have reported conﬂicting results [139,140].
In addition to suppressing gene expression of key proteins of
FA uptake, TNF-a reduces the transcript levels and expression
of many proteins involved in glyceroneogenesis, de novo FA
synthesis and esteriﬁcation (Fig. 3A). This leads to impaired
triglyceride storage in adipose tissue. Notably, most of these
genes are regulated by PPARc activity. Thus TNF-a may
mediate these eﬀects primarily through the inhibition of
PPARc activity and expression.4.2. TNF-a-induced lipolysis
The primary mechanism by which surplus fuel is made
available from adipocytes is through stimulated lipolysis.
This process liberates FA and glycerol from stored lipid
and is physiologically activated by hormones such as cate-
cholamines that stimulate cAMP production and PKA-
dependent phosphorylation of hormone-sensitive lipase
(HSL) and perilipins (Fig. 3B). TNF-a also potently stimu-
lates lipolysis and this may contribute to hyperlipidaemic
conditions. The increased availability of FFA may be shut-
tled into de novo ceramide production in adipose tissue
(Fig. 3A) but can also cause lipotoxicity-induced insulin
resistance in more distal organs.
Mechanistically, TNF-a can stimulate lipolysis in the ab-
sence of insulin, suggesting that TNF-a does not simply antag-
onise insulins anti-lipolytic actions. In addition, extracellular
glucose is required for TNF-a-mediated adipocyte lipolysis
[141], suggesting that a nutritional status or substrate availabil-
ity is required (e.g. provision of ATP). However, the mecha-
nism by which TNF-a induces adipocyte lipolysis has yet to
be completely elucidated. Nevertheless, some information is
available. Activation of a TNFR1-dependent pathway is both
necessary and suﬃcient [13,46,138,142] and the downstream
signals involve activation of ERK1/2, JNK, AMPK, IKK
and PKA, since inhibitors of these kinases can prevent TNF-
a-induced lipolysis [55,143,144]. Furthermore, a recent study
suggests that, in adipocytes, TNF-a signals via a trimeric G
protein, Gaq/11, and an adapter protein, b-arrestin-1, to medi-
ate ERK activation and lipolysis [145]. However, TNF-a-in-
duced activation of ERK1/2, JNK and IKK in adipocytes is
Fig. 3. Eﬀects of TNF-a on adipocyte lipid metabolism and lipolysis. (A) Pathways involved in adipocyte lipogenesis and their modulation by TNF-a.
Adipocytes take up glucose, glycerol and FFA from serum and convert these to triglycerides via numerous biochemical pathways. White boxes
indicate the nature of the pathways involved. TNF-a modulates the expression of many of the enzymes and other proteins that regulate these
pathways, thereby compromising adipocyte triglyceride storage. (B) Mechanisms of TNF-a-induced lipolysis in adipocytes. During lipolysis
triglycerides are hydrolysed into FFA and glycerol. Stimulus-induced lipolysis is mediated by hormone-sensitive lipase (HSL), whereas basal lipolysis
may be regulated by adipose triglyceride lipase (ATGL). Lipolysis is further regulated by the perilipins, a family of phosphoproteins that are localised
at the surface of lipid droplets in adipocytes. Perilipins normally inhibit lipolysis by preventing access of lipases to the lipid droplets. PKA stimulates
lipolysis by phosphorylating HSL and the perilipins. This activates HSL and enables it to access substrates in the lipid droplets. Downregulation of
cAMP by phosphodiesterases (PDE) or stimulation of Gia-coupled receptors abrogates PKA activation and thereby inhibits lipolysis. TNF-a
stimulates lipolysis via a glucose-dependent mechanism that likely involves transcriptional eﬀects. These may be mediated via JNK, ERK1/2 and
NFjB, resulting in upregulation of cAMP and downregulation of perilipins. Some of these eﬀects, such as downregulation of Gia subtypes, are
speciﬁc to rodent adipocytes. Arrows and gene names in red and green indicate upregulation and downregulation, respectively. PEPCK,
phosphoenolpyruvate carboxykinase; ACC, acetyl-CoA carboxylase; FAS, fatty acid synthase; FABP, fatty acid-binding protein; FAT, fatty acid
translocase; ACS, aceyl-CoA synthetase long chain; DGAT1, diacylglycerol acyltransferase 1; AQP7, aquaporin 7; GK, glycerol kinase; G3PDH,
glyceraldehyde-3-phosphate dehydrogenase; PFK, phosphofructokinase; PGK, phosphoglycerate kinase; PK, pyruvate kinase; PC, pyruvate
carboxylase; PDH, pyruvate dehydrogenase; TCA, tri-carboxylic acid; CPT1 carnitine palmitoyltransferase 1; OXA, oxaloacetate; PEP,
phosphoenol pyruvate; TG, triglyceride; VLDL, very low-density lipoprotein.
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duced lipolysis takes >6 h. This suggests that more distal
TNF-a-induced events remain to be identiﬁed, which are likely
to be controlled by transcriptional regulation (Fig. 3B). This is
consistent with the observations that TNF-a-induced lipolysisis sensitive to inhibition by TZD and NFjB inhibitors [146].
Furthermore, TNF-a treatment decreases the expression of
many genes involved in preventing lipolysis, such as Gia,
PDE3B, and perilipin [55,143,146–148] (Fig. 3B). Again,
TNF-a-mediated suppression of PPARc is likely to play an
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perilipin expression [149], and adenoviral expression of
PPARc S112A in 3T3-L1 adipocytes attenuates TNF-a-in-
duced decreases in TG content [70]. Nevertheless, a less-intui-
tive aspect that remains unresolved is that TNF-a also
decreases the expression of key lipolytic genes e.g. HSL,
ATGL, b1-AR and b3-AR [62,150]. In contrast, very few re-
ports have identiﬁed upregulation of lipolytic genes (e.g. b2-
AR upregulation in murine adipocytes) [151] (Fig. 3B).5. TNF-a and adipocyte diﬀerentiation
In addition to its eﬀects on lipid metabolism in mature adi-
pocytes, TNF-a may impair the lipid storage capacity of adi-
pose tissue by suppressing the recruitment and diﬀerentiation
of new adipocytes from precursor cells. The transcriptional
regulation of adipocyte diﬀerentiation has been extensively
studied, at least in vitro (for reviews see, [152,153]). In brief,
adipogenesis is driven by a transcriptional cascade, which is
characterised by the early, transient expression of C/EBPb
and C/EBPd. This precedes the induction of C/EBPa and
PPARc, the master regulators of adipogenesis. TNF-a inhibits
adipogenesis by preventing the induction of PPARc and C/
EBPa expression [47], thereby also preventing the induction
of genes that are responsible for the mature adipocyte pheno-
type (e.g. aP2, Glut4, ATGL) [62].5.1. Transcriptional targets of TNF-a in preadipocytes
Although TNF-a does not prevent the early expression of C/
EBPb or C/EBPd, it is likely that it inhibits the PPARc-medi-
ated expression of PPARc and C/EBPa, as has been discussed
above (see Section 2.1). This is proposed to be mediated via the
TAK1/TAB1/NIK kinase cascade to activate the p65/RelA
subunit of NFjB, which acts to sequester and prevent PGC/
PPARc complex function [57]. Currently, it is not clear
whether this is the primary target of TNF-a in preadipocytes,
as these cells tend to have very low levels of PPARc protein
(compared to mature adipocytes) and basal PPARc transcript
levels are not downregulated during TNF-a-induced anti-adi-
pogenesis [47]. Nonetheless, TZD treatment can antagonise
TNF-a-induced anti-adipogenesis [154], conﬁrming that
PPARc function is an important factor. Additionally,
MAP4K4 has been proposed to be a negative regulator of
PPARc and adipogenesis and its expression can be induced
by TNF-a (at least in adipocytes) [72]; however its role and
mechanism of action in TNF-a-induced anti-adipogenesis in
preadipocytes remains to be deﬁned.
Another negative regulator of adipogenesis that acts early
and suppresses PPARc and C/EBPa expression is Wnt10b
[155]. This is an important physiological factor involved in
lineage commitment and determination. The canonical Wnt
signalling pathway regulates the expression of Wnt target
genes via stabilisation of b-catenin, a co-activator of the T-cell
factor (TCF) family of transcription factors. Activation of this
pathway has been shown to inhibit PPARc expression and li-
pid accumulation both in vitro and in vivo. Conversely, PPARc
can negatively regulate canonical Wnt signalling [156]. Re-
cently, we noticed that TNF-a-induced suppression of PPARc
and C/EBPa coincides with enhanced expression of several re-
ported mediators of anti-adipogenesis that are also targets ofthe Wnt/b-catenin/TCF4 pathway. These include c-myc, cyclin
D1, and PPARdelta [157–160]. By abrogating b-catenin/TCF
signalling in 3T3-L1 cells, either via stable knockdown of b-
catenin or by overexpressing dominant-negative TCF4
(dnTCF4), we demonstrated that TNF-a-induced anti-adipo-
genesis is dependent on b-catenin/TCF4 activity [47]. There-
fore both TNF-a and canonical Wnt signalling pathways
seem to converge to inhibit adipogenesis at the level of
TCF4-dependent transcription. Intriguingly, TCF4 is also
called transcription factor 7 like-2 (TCF7L2), and recent stud-
ies have identiﬁed a strong association between at least 2 SNPS
in the TCF7L2 gene and type 2 diabetes [161,162]. These risk-
conferring genotypes are also strongly associated with im-
paired b-cell function, development and possibly survival
[163,164], while their adipose tissue expression may be associ-
ated with susceptibility of obese individuals to developing dia-
betes [165].
In addition to transcriptional events, TNFR-proximal
events required for TNF-a-induced anti-adipogenesis have
been elucidated. Here, both secreted and transmembrane
TNF-a can inhibit adipogenesis via TNFR1 and a functional
TNFR1-DD [4,47,166]. We have also shown that TNF-a-in-
duced maintenance of b-catenin during anti-adipogenesis re-
quires a functional TNFR1-DD [47]. A number of signals
downstream of this domain have been linked to suppression
of C/EBPa and PPARc. These include activation of ERK,
JNK, IKKb and ceramide synthesis via aSMase [56,167], each
of which has been suggested to exert anti-adipogenic eﬀects
[57,68,88,167,168]. However, this contrasts with other reports
suggesting that inhibition of JNK activation does not reverse
TNF-a-mediated suppression of PPARc expression [56,72].
Furthermore, ERK activation may stimulate PPARc expres-
sion during the early stages of adipogenesis, possibly by
enhancing C/EBPb activity [169,170], and NFjB activity
reportedly increases during adipogenesis without TNF-a
[171]. In contrast, exogenous ceramides do appear to mimic
TNF-a actions to inhibit adipogenesis by blocking the tran-
scriptional activity of C/EBPb, resulting in suppression of C/
EBPa and PPARc mRNA [172]. However, the identities of
the mediators in ceramide-induced anti-adipogenesis remain
unknown.
The dissection of upstream signals has been complicated by
the fact that, unlike adipocytes, preadipocytes can be particu-
larly sensitive to TNF-a-induced cell death during anti-adipo-
genesis. This is often enhanced when preadipocytes are pre-
treated with inhibitors of pro-survival signals, including
NFjB. Indeed, ceramides are well known inducers of apopto-
sis and this is entirely consistent with TNF-a-induced toxic sig-
nals emanating from the TNFR1-DD. However
pharmacological attempts to separate apoptotic signals from
anti-adipogenic signals have been notoriously diﬃcult. None-
theless, we and others have demonstrated that picomolar con-
centrations of TNF-a can inhibit adipogenesis without
inducing cell death [47,56]. Furthermore, in our recent study
we observed that knock down of b-catenin in 3T3-L1 preadi-
pocytes enhanced their sensitivity to TNF-a-induced cell
death. Taken together we speculate that the signals induced
by TNFR1-DD that lead to anti-adipogenesis in vitro are intri-
cately involved in cell survival as well as diﬀerentiation. Future
investigations should shed light on the nature of these events
and whether this is relevant to adipose tissue plasticity and/
or expansion in vivo.
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Whereas white adipose tissue (WAT) is primarily responsible
for storage and release of surplus fuel and generation of endo-
crine signals, brown adipose tissue (BAT) specialises in energy
expenditure via beta-oxidation that is coupled to thermogene-
sis [173]. The thermogenic capacity of BAT is an important
factor that contributes to the development of obesity-associ-
ated metabolic dysregulation. Indeed, obesity is associated
with reductions in thermogenically active BAT [32,53,174]
and transgenic mice lacking BAT become obese [173]. Con-
versely, increased UCP-1 expression in BAT is associated with
protection against metabolic syndrome in mice [175]. Numer-
ous studies suggest that TNF-a can modulate the thermogenic
capacity of BAT. However, these studies have yielded conﬂict-
ing results. For example, some reports suggest that administra-
tion of TNF-a increases BAT thermogenic activity, possibly by
upregulating UCP expression [176,177]. This is consistent with
the role of TNF-a in mediating increased energy expenditure in
catabolic states (e.g during cachexia). However, TNF-a may
mediate these eﬀects by targeting the central nervous system,
rather than BAT per se [178]. In contrast, some studies suggest
that TNF-a impairs BAT thermogenesis via downregulation of
UCP-1 and b3-AR expression [53,151,179,180]. These discrep-
ancies may result from diﬀerences in the experimental models
used. Nevertheless, compelling evidence for the role of TNF-
a in obesity-associated alterations in BAT thermogenesis
comes from studies in obese mice that lack TNF-a function.
Indeed, the obesity-associated decreases in UCP-1 and b3-
AR expression are attenuated in these mice [53]. Accordingly,
the lack of TNFRs signiﬁcantly improves the thermoadaptive
capacity of obese animals [53].
TNF-a may also compromise BAT thermogenesis by pro-
moting BAT atrophy or by impairing BAT diﬀerentiation.
Obesity is associated with increased apoptosis of brown adipo-
cytes [32], and several studies demonstrate that TNF-a can in-
duce apoptosis of brown adipocytes [32,53,181]. Similarly,
TNF-a may prevent the diﬀerentiation of brown adipocytes
[180,182]. Several studies suggest that adrenergic stimulation
promotes the transdiﬀerentiation of white adipocytes into
brown adipocytes (reviewed in [173]). Indeed, this phenome-
non is signiﬁcantly impaired in mice lacking the b3-AR [183].
Hence, by downregulating b3-AR expression in WAT, TNF-
a might indirectly attenuate the transdiﬀerentiation of white
adipocytes into brown adipocytes and thereby impair thermo-
genesis.
7. Summary
Although the oncolytic and cachectic properties of TNF-a
have been studied for over a century, the last decade alone
has unveiled many new aspects of TNF-a action on adipocyte
biology. In addition to its role in inducing insulin resistance in
adipose tissue, its local actions can impact on whole body insu-
lin sensitivity through increased FFA and altered adipokine
production. Furthermore, TNF-a can also signiﬁcantly alter
the lipid storage and oxidative capacity of adipose tissues.
Hence, adipose tissue-derived TNF-a can contribute to the
metabolic complications associated with obesity by altering
both adipose tissue function and expandability.
This multi-faceted nature of TNF-a is entirely in keeping
with its multifunctional classiﬁcation and so it should comeas no surprise that this potent cytokine is capable of stimulat-
ing a variety of signalling pathways in a context-dependent
manner. While the exact components of these signals remain
to be elucidated, it is becoming increasingly clear that a com-
plex network of signals emanating from the TNFR1 death do-
main converge with other signalling pathways to inﬂuence cell
fate determination and metabolism. It is likely that these sig-
nals will vary signiﬁcantly depending upon the amount and
duration of exposure, as well nutritional status and the extra-
cellular milieu. However, as new omic technologies become
available, it should be possible to investigate the inﬂuence of
these additional factors and better our understanding at a
more global, systems level.
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